MBRX Key Statistics, Chart & Performance
The current stock price of MBRX is 4.14 USD. In the past month the price decreased by -60.57%. In the past year, price decreased by -90.08%.
MBRX Latest News, Press Relases and Analysis
MBRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.74 | 396.44B | ||
| AMGN | AMGEN INC | 14.91 | 175.55B | ||
| GILD | GILEAD SCIENCES INC | 14.82 | 150.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.89 | 114.05B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.66 | 78.80B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 768.82 | 51.80B | ||
| INSM | INSMED INC | N/A | 42.33B | ||
| NTRA | NATERA INC | N/A | 31.12B | ||
| BIIB | BIOGEN INC | 10.28 | 25.25B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.36 | 22.00B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.28B | ||
| INCY | INCYTE CORP | 15.21 | 19.17B |
Related stock screener links
About MBRX
Company Profile
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Houston, Texas and currently employs 17 full-time employees. The company went IPO on 2016-06-02. The firm is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). The company has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).
Company Info
MOLECULIN BIOTECH INC
5300 Memorial Dr Ste 950
Houston TEXAS 77007 US
CEO: Walter V. Klemp
Employees: 17
Phone: 17133005160
MOLECULIN BIOTECH INC / MBRX FAQ
What does MBRX do?
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Houston, Texas and currently employs 17 full-time employees. The company went IPO on 2016-06-02. The firm is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). The company has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).
What is the stock price of MOLECULIN BIOTECH INC today?
The current stock price of MBRX is 4.14 USD. The price decreased by -11.73% in the last trading session.
Does MBRX stock pay dividends?
MBRX does not pay a dividend.
How is the ChartMill rating for MOLECULIN BIOTECH INC?
MBRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does MOLECULIN BIOTECH INC belong to?
MOLECULIN BIOTECH INC (MBRX) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for MBRX stock?
MOLECULIN BIOTECH INC (MBRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-30.31).
What is the ownership structure of MOLECULIN BIOTECH INC (MBRX)?
You can find the ownership structure of MOLECULIN BIOTECH INC (MBRX) on the Ownership tab.
MBRX Technical Analysis
MBRX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to MBRX. MBRX may be in some trouble as it scores bad on both profitability and health.
MBRX Financial Highlights
Over the last trailing twelve months MBRX reported a non-GAAP Earnings per Share(EPS) of -30.31. The EPS decreased by -161.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -203.2% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MBRX Forecast & Estimates
9 analysts have analysed MBRX and the average price target is 170 USD. This implies a price increase of 4006.28% is expected in the next year compared to the current price of 4.14.